ALKS News and Press, Alkermes plc From 02/15/24

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024 PR Newswire — Total Revenues of $1.66 Billion in 2023; Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Yea...

Propanc Biopharma Inc (PPCB) is expected to report for Q2 2024 Bank of Georgia Group Plc (BDGSF) is expected to report for quarter end 2023-12-31 Arch Resources Inc. Class A (ARCH) is expected to report $6.9 for Q4 2023 Bloom Energy Corporation Class A (BE) is expected to report $-0.0...

2024-02-14 11:25:34 ET More on Alkermes Alkermes: Additional Narcolepsy Data Could Lead The Way To The Next Stage Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet Alkermes to sell Athlone facility in Ireland to Novo Nordisk for $92.5M Seeking A...

Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 15, 2024 PR Newswire DUBLIN , Feb. 8, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET ( 1:00 p.m. GMT ) on ...

2024-02-02 02:15:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The quest for prime biotech stocks for gains will always be relevant. Moreover, 2024 promises a surge in technology and science, positioning biotech firms at the forefront of novel medical ...

2024-01-26 15:33:29 ET Summary Alkermes plc expects to have additional results from the phase 1b proof-of-concept study, using ALKS-2680 for the treatment of patients with narcolepsy, in the 1st half of 2024. An update on the advancement of a phase 2 study, using ALKS-2680 for the...

2024-01-26 14:15:33 ET Summary Alkermes plc, a neuroscience company, has undergone restructuring and simplification, including spinning out its oncology business and selling its manufacturing facility. Despite a turbulent year, Alkermes' stock price remains relatively stable, but ...

Alkermes to Present at the 42nd Annual J.P. Morgan Healthcare Conference PR Newswire DUBLIN , Jan. 3, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops , will provide a corporate overview and u...

Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorphan) PR Newswire — Results Demonstrated that LYBALVI was Generally Well Tolerated With Stability of Body Weight an...

2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...